Background The blood coagulation system is activated in the acute phase of unstable angina and acute myocardial infarction. However, it remains unclear whether augmented function of the hemostatic mechanism serves only as a marker of the acute thrombotic episode or whether a hypercoagulable state persists for a prolonged period after clinical stabilization.
Methods and Results We prospectively measured the plasma concentrations of prothrombin fragment 1+2 (F1+2) and fibrinopeptide A (FPA) in consecutive patients presenting with unstable angina (n=80) or acute myocardial infarction (n=32), respectively. At 6 months, plasma determinations were repeated in patients experiencing an uneventful clinical course (unstable angina, n=57; myocardial infarction, n=23). We quantitated the plasma levels of F1+2 and FPA in control patients with stable angina (n=37) or healthy individuals (n=32) who were matched for age and sex. The median plasma concentrations of F1+2 and EPA are significantly higher in patients presenting with unstable angina (F1+2, 1 .08 nmol/L; FPA, 2.4 nmol/L) or acute myocardial infarction (F1+2, 1.27 I n the acute phase of unstable angina and myocardial infarction, the hemostatic mechanism is known to be activated. Plasma levels of fibrinopeptide A (FPA), cross-linked fibrin, platelet factor 4, and fibrinogen-fibrin degradation products are elevated, signaling production and lysis of the intracoronary fibrin-platelet thrombus.1-4 However, it remaing unclear whether increased activity of the hemostatic mechanism is only a marker of the acute thrombotic episode or whether a hypercoagulable state persists for a prolonged period after the apparent resolution of these disorders or even precedes their appearance. The relation between the postulated hypercoagulable state and acute coronary syndromes has been difficult to assess because of the absence of reliable techniques for measuring changes in blood coagulability.
The prothrombin fragment 1+2 (Fi+2)s56 and FPA78 immunoassays allow coagulation system activity to be monitored under in vivo conditions. F1+2 is a 31-kd polypeptide released from the amino terminal end of prothrombin during its conversion to thrombin that quantifies factor Xa activity. FPA is a 16-amino-acid peptide cleaved from the a chain of fibrinogen during its transition to fibrin that detects thrombin action. The occurrence of elevated plasma concentrations of Fl+2, in the presence of augmented plasma levels of FPA, signifies increased production of factor Xa, which is able to generate sufficient free thrombin to initiate thrombus formation. The occurrence of elevated plasma concentrations of F1+2, in the presence of normal or slightly increased plasma levels of FPA, signifies enhanced production of factor Xa, which is unable to generate sufficient free thrombin to initiate thrombus formation. This observation indicates accelerated hemostatic mechanism function, which is termed a hypercoagulable state. 9 In the present investigation, we prospectively measured the plasma concentrations of F1+2 and FPA in patients with a first episode of unstable angina or myocardial infarction and compared the results with those of control patients with stable angina or healthy individuals. We then reevaluated patients with acute coronary syndromes who exhibited an uneventful clinical course over a subsequent 6-month 
Inclusion Criteria and Patient Subgroups
Patients were prospectively assigned to diagnostic subgroups or excluded from investigation by the physician in charge of the emergency department. A log of all hospital admissions was kept during the recruitment phase. Unstable angina was defined as chest pain occurring at rest that was accompanied by transient ischemic changes on the ECG (ie, ST-segment elevation or depression .1 mm 0.08 second after the J point or pseudonormalization of previously negative T waves) with serum levels of creatine kinase-MB fraction of less than twice the upper limit of normal. Acute myocardial infarction was defined as prolonged chest pain occurring at rest accompanied by ST-segment elevation evolving into pathological Q-wave or T-wave inversion confirmed by an elevation of the creatine kinase-MB fraction of more than twice the upper limit of normal. Only patients reporting the onset of symptoms within 6 hours of presentation were eligible to enter the study.
Exclusion Criteria
Patients with comorbid conditions known to alter coagulation system activity or decrease clearance of activation fragments or who were taking drugs that affect hemostatic mechanism function10 were deemed ineligible for the study. Among the 137 patients with unstable angina, 57 patients were excluded because they had one of the following: incorrect diagnosis (3 patients); concomitant peripheral vascular disorders or valvular heart disease (11 patients); history of cerebrovascular accident, coronary artery bypass surgery, angioplasty, or acute myocardial infarction within the preceding 6 months (21 patients); disorders of hemostasis (1 patient); malignancy (1 patient); severely limited venous access (12 patients); renal or hepatic insufficiency (7 patients); or rheumatoid arthritis (1 patient). Among 50 patients with myocardial infarction, 18 patients were excluded because of incorrect diagnosis (1 patient), difficult venous access (8 patients), peripheral vascular disease (4 patients), renal insufficiency (1 patient), valvular heart disease (2 patients), or echocardiographic evidence of intracardiac thrombus (2 patients).
Study Protocol
Screening for the study was done in the emergency department. After determination of eligibility and inclusion into the study, venous blood samples were collected for baseline biochemical and coagulation analyses, and standardized medical therapy was started immediately. Blood withdrawal was performed before any invasive procedure, including the insertion of intravenous lines. Patients with unstable angina received intravenous heparin (100-U/kg bolus followed by 10-to 20-U/kg infusion to maintain the activated partial thromboplastin time at 1.5 to 2 times control values), intravenous nitroglycerin (0.1 to 0.5 ,ug/kg per minute), and oral atenolol (50 to 100 mg/d) or diltiazem (180 to 360 mg/d), whereas patients with myocardial infarction were treated with thrombolytic agents (1.5 million U streptokinase over 60 minutes, 100 mg tissuetype plasminogen activator over 3 hours, or 30 U anistreplase over 5 minutes) in conjunction with heparin (5000-U bolus followed by 1000 U/h adjusted to maintain the activated partial thromboplastin time above 2 times control values), aspirin (325 mg/d), and a-blockers (50 to 100 mg/d atenolol).
The patients were followed for the occurrence of cardiac events, defined as death, myocardial infarction, or the need for coronary revascularization. Before discharge, the patients underwent coronary angiography. In the absence of disease of the left main coronary artery, the decision to perform revascularization was made on the basis of the patient's symptomatic response to the medical regimen and required at least one episode of angina at rest with accompanying ischemic ECG changes. While in the hospital, all patients stopped smoking, and on discharge, they were enrolled in a program to control addictive behavior that has a documented high rate of success.1" Long-term treatment was standardized by administering a combination of aspirin (325 mg/d), transdermal nitroglycerin (10 to 20 mg/d), atenolol (50 to 100 mg/d), diltiazem (180 to 360 mg/d), and/or nifedipine (40 to 80 mg/d). Follow-up visits were scheduled at 1, 3, and 6 months. At the 6-month visit, the patients with an uneventful clinical course underwent 24-hour Holter monitoring to detect silent ischemia, echocardiography to uncover intracardiac thrombi, and venous blood sampling for follow-up analyses. The plasma concentrations of F112 and FPA have been shown to represent stable parameters that are characteristic of individuals over an extended time period.12 To demonstrate that the above conclusion was valid during our investigation, we drew an additional blood sample between the fourth and seventh months from a randomly selected subgroup of the study population consisting of 21 patients with unstable angina and 12 patients with myocardial infarction. The patients in the randomly selected subgroup exhibited clinical and angiographic characteristics similar to those of the overall population.
Control Population
We evaluated control patients with stable angina or healthy individuals who were matched for age and sex. Patients with stable angina but no prior history or findings of myocardial infarction, unstable angina, coronary revascularization, silent ischemia, or peripheral vascular disease were selected from a pool of individuals hospitalized for elective cardiac catheterization. Stable angina was defined as a history of chest pain induced by exercise or usual daily activity lasting more than 6 months with the development of at least 1 mm of ST-segment depression during the exercise test and with significant coronary artery disease at angiography. The medical regimen of patients with stable angina included a combination of aspirin Blood samples for biochemical and coagulation analyses were taken from patients with stable angina during hospitalization for cardiac catheterization, and specimens were collected from healthy controls during routine visits to the blood bank. In 11 patients with stable angina who were not undergoing coronary revascularization and in 12 randomly selected healthy volunteers, additional blood samples were obtained after 6 months.
Measurement of Coagulation System Activation and Variability of the Assays
Venipuncture was performed atraumatically by two specially trained investigators with 19-gauge butterfly infusion sets using a two-syringe technique. After the first 4 mL of blood was discarded, samples were collected directly into refrigerated vacutainers containing an anticoagulant mixture composed of a thrombin inhibitor, EDTA, and aprotinin (purchased from BykSangtec). The ratio of anticoagulant to blood used was 1: 9 (vhv). (Table 2) . Patients with unstable angina and myocardial infarction exhibit a similar initial extent of elevation of the two hemostatic system markers. Plasma levels of F1+2 and FPA were statistically indistinguishable in patients with stable angina compared with age-and sex-matched healthy individuals despite significant coronary artery disease and a long-term drug regimen similar to that of patients with acute coronary syndromes after hospitalization (Tables 1 and 2 ). Detailed stratification of the patients with regard to the number of diseased vessels revealed no statistically significant difference in the levels of hemostatic markers compared with the severity of coronary artery disease (Table 3) . Detailed comparison of patients with stable angina taking particular combinations of drugs with ageand sex-matched healthy individuals showed no significant differences in the levels of hemostatic markers (data not shown).
Patients with unstable angina or myocardial infarction were followed over 6 months. According to the clinical guidelines of our institution, most of the patients with unstable angina received chronic treatment with diltiazem, whereas most of the patients with myocardial infarction were treated with 83-blockers. Based on the occurrence of cardiac events over the study period, the two cohorts of patients were divided into subpopulations with either an eventful or an uneventful clinical course (Table 2 ). In the population with unstable angina, 2 patients developed myocardial infarction and 17 patients required coronary revascularization. In the population with acute myocardial infarction, 3 At 6 months, patients with stable angina or healthy blood donors have plasma levels of F1+2 or FPA that are similar to those observed during the first evaluation ( Table 2 ). The median changes of F1+2 and FPA in patients with stable angina are -0.04 nmol/L (99% CI, -0.3 to 0.17; P=NS) and 0.1 nmol/L (99% CI, -0.1 to 0.2; P=NS), respectively. The median changes of F1+2 and FPA in healthy blood donors are 0.02 nmol/L (99% CI, -0.14 to 0.04; P=NS) and 0.1 nmol/L (99% CI, -0.14 to 0.4; P=NS), respectively (Figure) .
The subpopulation with unstable angina and an uneventful clinical course includes 34 patients with abnormal plasma levels of F1+2 at admission (prevalence, 60%; 99% CI, 42 to 75) and 37 patients at 6 months (prevalence, 68%; 99% CI, 47 to 80). The FPA values has been widely interpreted as demonstrating that coagulation system hyperactivity in these disorders is restricted to the time period during which the coronary thrombus is generated. However, the present investigation, using the F1+2 assay that monitors an earlier point in the coagulation cascade, reveals that abnormalities of the hemostatic mechanism persist in patients with acute coronary syndromes long after clinical stabilization and are consistent with the presence of an hypercoagulable state.9 Thus, our studies confirm results obtained in much larger clinical trials using less specific coagulation system assays, which show an association between hemostatic system abnormalities and mortality from ischemic heart disease. 17 The occurrence of a persistent hypercoagulable state in patients with unstable angina or myocardial infarction appears to be independent of coronary artery atherosclerosis or drug ingestion. The stratification of patients with acute coronary syndromes with regard to the number of diseased vessels reveals no significant differences in hemostatic markers, and no such abnormality is noted in patients with stable angina with severe coronary artery disease on a similar medical regimen. We suspect that molecular abnormalities of the hemostatic mechanism-blood vessel wall are responsible for the observed hypercoagulable state. Thus, the present investigation raises the interesting issue that increased activity of the hemostatic mechanism could predate the onset of acute coronary syndromes, and this hypothesis is under examination in a large prospective trial (Northwick Park Heart Study II).1718 However, it is difficult to exclude the possibility that patients with acute coronary syndromes, compared with those with stable angina, have a considerably more extensive atherosclerotic process outside the coronary circulation or atherosclerotic changes that more readily activate the coagulation mechanism.
We have previously hypothesized that increased activity of the hemostatic system, as observed in the present investigation, might sensitize individuals to respond at a higher frequency to relatively minor prothrombotic stimuli with overt thrombotic events.9 Prior studies have provided support for this hypothesis in congenital thrombophilic states such as protein C and protein S deficiency.1920 It obviously will be critical to determine whether the presence of a hypercoagulable state in patients who exhibit acute coronary syndromes is predictive of the subsequent development of major cardiac events.
The observation that patients with acute coronary syndromes exhibit an increased basal level of activation of the coagulation system long after clinical stabilization may have important implications with regard to the pathophysiology and treatment of acute coronary syndromes. It is tempting speculate that the higher occurrence of cardiac events in patients with unstable angina21 or myocardial infarction22 compared with those with stable angina23 may be in part attributable to the persistent hypercoagulable state observed in the first two groups. Indeed, the successful efforts at secondary prevention of unstable angina and myocardial infarction with warfarin therapy24-26 could be due to suppression of the persistent activation of the hemostatic mechanism. It is reasonable to propose that detection of the hypercoagulable state with the F1+2 assay could pinpoint individuals most likely to benefit from prolonged anticoagulant therapy and provide a means for determining the optimal levels of drug to administer. The amounts of oral anticoagulant needed to suppress high plasma levels of F1+2 into the normal range are likely to be significantly less than those indicated by standard monitoring approaches based on the prothrombin time that could significantly reduce bleeding complications.27,28
